APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Public ClinicalTrials.gov record NCT04214860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Study identification
- NCT ID
- NCT04214860
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Aprea Therapeutics
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- APR-246 Drug
- Azacitidine Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2019
- Primary completion
- Jan 13, 2022
- Completion
- Jan 13, 2022
- Last update posted
- Mar 16, 2025
2019 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06511 | — |
| H. Lee Moffitt CC | Tampa | Florida | 33612 | — |
| Northwestern Medicine | Chicago | Illinois | 60611 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Weill Cornell Cancer Center | New York | New York | 10021 | — |
| Memorial Sloan Kettering CC | New York | New York | 10065 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04214860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04214860 live on ClinicalTrials.gov.